Latest Breaking News On - Promising efficacy - Page 1 : comparemela.com

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient.

United statesAngelos stergiouBruce mackleGenfleet therapeutics shanghai incLifesci advisorsGlobenewswire incLife sciences group incMemorial sloan kettering cancer centerOffice of orphan products developmentDrug administrationGenfleet therapeutics incPromising efficacyClinical responsePeripheralt cell lymphomasComplete metabolic response continuing treatmentComplete response

NuCana plc: NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana plc: NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomRheinland pfalzCity ofHughs griffithChris brinzeyExchange commissionCompany annual report on formAnnounced encouraging updatesPromising efficacyData updates expectedAnticipated cash runwayChief executivePrivate securities litigation reform actAnnual reportCondensed consolidated statementsThree months

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update - NuCana (NASDAQ:NCNA)

Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data Pipeline Continues to Advance with Data Updates Expected for all Programs in 2024 Well Capitalized with

United kingdomCity ofChris brinzeyHughs griffithExchange commissionCompany annual report on formEncouraging updatesPromising efficacyData updates expectedAnticipated cash runwayChief executivePrivate securities litigation reform actAnnual reportCondensed consolidated statementsFinancial positionCash flows

Roche : to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders -November 02, 2023 at 09:21 am EDT

Roche : to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders -November 02, 2023 at 09:21 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoVenclexta venclyxtoPolatuzumab vedotinGlofitamab monotherapyRoche groupAmerican society of hematologyAmerican societyAnnual meetingRefractory mantle cell lymphomaRefractory largeb cell lymphomaExtended follow upPivotal phaseSubgroup analysesPrior chimeric antigen receptort cell therapyBaseline total metabolic tumor volume

SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas

SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Angelos stergiouBruce mackleLife sciences receives fast track designationGenfleet therapeutics shanghai incLife sciences group incLifesci advisorsMemorial sloan kettering cancer centerDrug administrationSciences receives fast track designationRefractory peripheralt cellPromising efficacyClinical responsePeripheralt cell lymphomasTrack designation acceleratesSciences groupFast track designation